Form 4: Alto Neuroscience CFO Acquires 135,000 Stock Options

Nicholas Conrad Smith, CFO of Alto Neuroscience, acquired 135,000 employee stock options on February 5, 2025.

Summary

• Nicholas Conrad Smith, the Chief Financial Officer & CBO of Alto Neuroscience, Inc., filed a Form 4 on February 7, 2025.
• The filing reports a transaction that occurred on February 5, 2025, where Smith acquired 135,000 employee stock options.
• The exercise price of the options is $4.20.
• The options vest over time, with 25% vesting on February 5, 2026, and the remainder vesting monthly over the following 48 months, contingent upon continuous service.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It reflects a standard insider transaction (stock option grant) which suggests confidence from the CFO in the company's future, but doesn't provide any groundbreaking information.

Positives

• The acquisition of stock options by a key executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the CFO's acquisition of stock options, which is a common form of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options as part of their executive compensation plans.
• The vesting schedule of 25% after one year followed by monthly vesting over the next four years is a typical arrangement to incentivize long-term commitment.

Stakeholder Impact

• The acquisition of stock options by the CFO could have a slightly positive impact on shareholder sentiment, as it aligns the executive's interests with those of the shareholders.

Key Dates